Innate Pharma (IPHA) said Wednesday it will seek approval from shareholders to change its governance from the current executive board/supervisory board structure to one with a CEO and board of directors.
The change, which aims to simplify and align the company's governance with international standards, will be proposed at the annual general meeting on May 22, Innate Pharma said.
If shareholders approve the change, current supervisory board chairwoman Irina Staatz-Granzer would be appointed chairwoman of the board, and current executive board chairman Jonathan Dickinson would be appointed CEO, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.